Hjem
Jørn Skavlands bilde

Jørn Skavland

Overingeniør
  • E-postJorn.Skavland@uib.no
  • Telefon+47 55 58 53 36
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

My research projects are focused on understanding cellular signaling (phosphorylation) and can be divided in four topics.

-          Basal research understanding signaling node cascade.

-          Aberrant signaling pattern in chronic and acute myeloid leukemia.

-          Phospho-signaling and hematologic pattern to immunologic response.

-          Mass Cytometry – a new instrument analyzing over 40 parameters in a single cell manner.                      

I have shown that analyzing in vivo patient whole blood, the change in the signaling pattern shortly after start a new treatment regime reflects the drug that is given. Using this methodology I’m involved in several cancer sub-studies - local and international.

 

Monitoring signaling patterns in patients starting a new treatment is likely to be of important for patient progress, early drug evaluation, as well as increased understanding of complex diseases. 

Vitenskapelig artikkel
  • 2019. Whole blood preservation methods alter chemokine receptor detection in mass cytometry experiments. JIM - Journal of Immunological Methods.
  • 2019. Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • 2018. Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology.
  • 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 216-227.
  • 2015. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • 2012. In vitro screening for putative psoriasis-specific antigens among wheat proteins and peptides. British Journal of Dermatology. 67-73.
  • 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
Vitenskapelig foredrag
  • 2019. Comprehensive characterization and kinetics of circulating lymphocytes in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
Doktorgradsavhandling
  • 2013. Risk stratification and therapy response monitoring by phosphoprotein profiles in acute myeloid leukaemia.
Sammendrag/abstract
  • 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
Poster
  • 2018. Comprehensive characterization of circulating T follicular helper cells and plasmablasts in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
Vitenskapelig oversiktsartikkel/review
  • 2016. Single-cell proteomics: Potential implications for cancer diagnostics. 579-589.
  • 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. 269-281.

Se fullstendig oversikt over publikasjoner i CRIStin.

no.linkedin.com/pub/jørn-skavland/52/680/795/

 

http://scholar.google.com/citations?user=diZCY1MAAAAJ